Indivior Pharmaceuticals Inc(INDV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 12.2 | EPS (ttm) | 2.82 | Insider Own | 3.22% | Shs Outstand | 124.8M | Perf Week | -1.21% |
| Market Cap | 4.05B | Forward P/E | 7.44 | EPS next Y | 9.44% | Insider Trans | -1.81% | Shs Float | 120.8M | Perf Month | -12.1% |
| Enterprise Value | 4.34B | PEG | 0.3 | EPS next Q | 1.06 | Inst Own | 91.69% | Short Float | 9.36% | Perf Quarter | -9.63% |
| Income | 0.35B | P/S | 3.04 | EPS this Y | 68.86% | Inst Trans | -11.62% | Short Ratio | 5.41 | Perf Half Y | 9.64% |
| Sales | 1.33B | P/B | - | EPS next 5Y | 24.63% | ROA | 26.44% | Short Interest | 11.30M | Perf YTD | -4.26% |
| Book/sh | -1.76 | P/C | 18.26 | EPS past 3/5Y | - | ROE | - | 52W High | -19.76% ($42.81) | Perf Year | 50.86% |
| Cash/sh | 1.88 | P/FCF | - | Sales past 3/5Y | 11.2% 13.88% | ROIC | 121.58% | 52W Low | 54.59% ($22.22) | Perf 3Y | 55.43% |
| Dividend Est. | - | EV/EBITDA | 7.91 | EPS Y/Y TTM | 305.85% | Gross Margin | 83.78% | Volatility(W/M) | 2.26% 2.73% | Perf 5Y | 146.68% |
| Dividend TTM | - | EV/Sales | 3.26 | Sales Y/Y TTM | 13.55% | Oper. Margin | 39.94% | ATR (14) | 1.02 | Perf 10Y | 61.65% |
| Dividend Ex-Date | - | Quick Ratio | 0.66 | EPS Q/Q | 588.52% | Profit Margin | 26.65% | RSI (14) | 33.2 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.84 | Sales Q/Q | 13.58% | SMA20 | -2.87% ($35.36) | Beta | 1.18 | Target Price | $49 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/3 | SMA50 | -9.43% ($37.93) | Rel Volume | 0.89 | Prev Close | $34.22 |
| Employees | 838 | LT Debt/Eq | - | EPS/Sales Surpr. | 32.29% 12.01% | SMA200 | -3.72% ($35.68) | Avg Volume(3M) | 2.09M | Price | $34.35 |
| IPO | 2014/12/29 | Option/Short | Yes/Yes | Trades | 17169 | Volume | 1,865,882 | Change | 0.38% |
Company
INDV is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 A specialty pharmaceutical company that develops and sells treatments for opioid use disorder. It leads the opioid use disorder treatment market through products such as the once-monthly injectable therapy SUBLOCADE and a sublingual film treatment, and has secured a differentiated position in the long-acting injectable segment. It is a specialty pharmaceutical company focused on addiction treatment.
Over the past 1 year, roughly in the middle
20% below its 1-year high.
INDV has weak earning power
39.94% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +68.9% this year.
Tap to view numbers
The price looks about right
Trading at 12.2 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +55.4% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 91.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PSCH 0.02%
OMFS 0.02%
XSMO 0.02%
XPH 0.02%
PILL 0.01%It ranks #4 in the industry
Based on market cap of $4B.
INDV $4B PER 12.2
TAK $59B PER -
TEVA $45B PER 64.2
HLN $41B PER 18.9
FAQ
What kind of company is INDV?
INDV belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of INDV?
The market cap of INDV is approximately $4.1B, ranking 1,538 within its sector.
What is the P/E ratio of INDV?
INDV has a P/E ratio of approximately 12.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for INDV?
INDV has recorded a 52-week high of $42.81 and a low of $22.22.
